Biotronik
This article was originally published in The Gray Sheet
Executive Summary
Lake Oswego, Oregon-based firm plans to launch the mycroPhylax and Phylax XM implantable cardioverter defibrillators in the U.S. on Nov. 23 following PMA approval by FDA. The 54 cc, 89 gram mycroPhylax and the 69 cc, 109 gram Phylax XM have the same diagnostics, detection and therapy capabilities. The ICDs will be priced comparably to similar ICDs on the market, Biotronik says